Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1993 Jun 1;177(6):1643–1650. doi: 10.1084/jem.177.6.1643

Contribution of direct and indirect recognition pathways to T cell alloreactivity

PMCID: PMC2191044  PMID: 7684431

Abstract

T cells from an HLA-DR11/DR12 responder were stimulated in mixed lymphocyte culture with cells carrying the DR1 antigen. After priming, T cells proliferated in response to both DR1-positive-stimulating cells and a peptide derived from a polymorphic region of the HLA-DR beta 1*0101 chain presented by responder's antigen-presenting cells (APC). The dominant epitope recognized by the primed T cells corresponded to residue 21-42 and was presented by the responder's HLA-DR12 antigen. The DR1 peptide-reactive T cells express T cell receptor V beta 3. The results demonstrate that allopeptides derived from the processing and presentation of donor major histocompatibility complex molecules by host-derived APC trigger alloreactivity. The frequency of T cells engaged in the indirect pathway of allorecognition is about 100-fold lower than that of T cells participating in the direct recognition of native HLA-DR antigen. However, indirect allorecognition may play an important role in chronic allograft rejection, a phenomenon that is mediated by the activation of T helper cells and of alloantibody- producing B cells.

Full Text

The Full Text of this article is available as a PDF (871.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell J. I., Denney D., Jr, Foster L., Belt T., Todd J. A., McDevitt H. O. Allelic variation in the DR subregion of the human major histocompatibility complex. Proc Natl Acad Sci U S A. 1987 Sep;84(17):6234–6238. doi: 10.1073/pnas.84.17.6234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benichou G., Takizawa P. A., Ho P. T., Killion C. C., Olson C. A., McMillan M., Sercarz E. E. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides. J Exp Med. 1990 Nov 1;172(5):1341–1346. doi: 10.1084/jem.172.5.1341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Benichou G., Takizawa P. A., Olson C. A., McMillan M., Sercarz E. E. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med. 1992 Jan 1;175(1):305–308. doi: 10.1084/jem.175.1.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bradley J. A., Mowat A. M., Bolton E. M. Processed MHC class I alloantigen as the stimulus for CD4+ T-cell dependent antibody-mediated graft rejection. Immunol Today. 1992 Nov;13(11):434–438. doi: 10.1016/0167-5699(92)90069-J. [DOI] [PubMed] [Google Scholar]
  5. Burroughs A. K., Butler P., Sternberg M. J., Baum H. Molecular mimicry in liver disease. Nature. 1992 Jul 30;358(6385):377–378. doi: 10.1038/358377a0. [DOI] [PubMed] [Google Scholar]
  6. Chen B. P., Madrigal A., Parham P. Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule. J Exp Med. 1990 Sep 1;172(3):779–788. doi: 10.1084/jem.172.3.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fangmann J., Dalchau R., Fabre J. W. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med. 1992 Jun 1;175(6):1521–1529. doi: 10.1084/jem.175.6.1521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harris P. E., Liu Z., Suciu-Foca N. MHC class II binding of peptides derived from HLA-DR 1. J Immunol. 1992 Apr 1;148(7):2169–2174. [PubMed] [Google Scholar]
  9. Ichikawa T., Nakayama E., Uenaka A., Monden M., Mori T. Effector cells in allelic H-2 class I-incompatible skin graft rejection. J Exp Med. 1987 Oct 1;166(4):982–990. doi: 10.1084/jem.166.4.982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lechler R. I., Lombardi G., Batchelor J. R., Reinsmoen N., Bach F. H. The molecular basis of alloreactivity. Immunol Today. 1990 Mar;11(3):83–88. doi: 10.1016/0167-5699(90)90033-6. [DOI] [PubMed] [Google Scholar]
  11. Liu Z., Braunstein N. S., Suciu-Foca N. T cell recognition of allopeptides in context of syngeneic MHC. J Immunol. 1992 Jan 1;148(1):35–40. [PubMed] [Google Scholar]
  12. Liu Z., Sun Y. K., Xi Y. P., Harris P., Suciu-Foca N. T cell recognition of self-human histocompatibility leukocyte antigens (HLA)-DR peptides in context of syngeneic HLA-DR molecules. J Exp Med. 1992 Jun 1;175(6):1663–1668. doi: 10.1084/jem.175.6.1663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lombardi G., Sidhu S., Batchelor J. R., Lechler R. I. Allorecognition of DR1 by T cells from a DR4/DRw13 responder mimics self-restricted recognition of endogenous peptides. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4190–4194. doi: 10.1073/pnas.86.11.4190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Murphy D. B., Lo D., Rath S., Brinster R. L., Flavell R. A., Slanetz A., Janeway C. A., Jr A novel MHC class II epitope expressed in thymic medulla but not cortex. Nature. 1989 Apr 27;338(6218):765–768. doi: 10.1038/338765a0. [DOI] [PubMed] [Google Scholar]
  15. Rosenberg A. S., Mizuochi T., Sharrow S. O., Singer A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med. 1987 May 1;165(5):1296–1315. doi: 10.1084/jem.165.5.1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rosenberg A. S., Munitz T. I., Maniero T. G., Singer A. Cellular basis of skin allograft rejection across a class I major histocompatibility barrier in mice depleted of CD8+ T cells in vivo. J Exp Med. 1991 Jun 1;173(6):1463–1471. doi: 10.1084/jem.173.6.1463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rudensky AYu, Rath S., Preston-Hurlburt P., Murphy D. B., Janeway C. A., Jr On the complexity of self. Nature. 1991 Oct 17;353(6345):660–662. doi: 10.1038/353660a0. [DOI] [PubMed] [Google Scholar]
  18. Sprent J., Schaefer M., Lo D., Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med. 1986 Apr 1;163(4):998–1011. doi: 10.1084/jem.163.4.998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Suciu-Foca N., Reed E., Marboe C., Harris P., Yu P. X., Sun Y. K., Ho E., Rose E., Reemtsma K., King D. W. The role of anti-HLA antibodies in heart transplantation. Transplantation. 1991 Mar;51(3):716–724. doi: 10.1097/00007890-199103000-00033. [DOI] [PubMed] [Google Scholar]
  20. de Koster H. S., Anderson D. C., Termijtelen A. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. J Exp Med. 1989 Mar 1;169(3):1191–1196. doi: 10.1084/jem.169.3.1191. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES